Evidence map›Paper›PMID 28119804›Full record

ReviewActa pharmaceutica Sinica. B2017

Targeting calcium signaling in cancer therapy.

Chaochu Cui, Robert Merritt, Liwu Fu, Zui Pan

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 325 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
325citing papers in PubMed, 1 pooled it
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

325 citing papers in PubMed, 1 synthesis or guideline pooled it, 597 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. [Force-regulation mechanism of E-selectin mediated adhesion and activation of MDA-MB-231 cells under fluid shear stress].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Article
  11. Review
  12. A systemic immunogenic reactor leveraging modifiedActa pharmaceutica Sinica. B · 2026
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

265 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Chaochu CuiState Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA.
Robert MerrittDepartment of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Liwu FuState Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zui PanDepartment of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX 76019, USA.
Sun Yat-sen University · CNThe Ohio State University · US

Funding

Oncogenic Function of Ca2+ Channel Orai1 in Esophageal CarcinogenesisR01CA185055 · NCI · OHIO STATE UNIVERSITY · PI CHEN, TONG, PAN, ZUI · 2015 to 2019
$1.6M
NCI NIH HHS R01 CA185055
6 · The paper itself

Abstract

The intracellular calcium ions (Ca

Indexed as

20-GPPD, 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiolApoptosisCa2+ channelsCaM, calmodulinCaMKII, calmodulin-dependent protein kinase IICancer therapyCBD, cannabidiolCBG, cannabigerolCell proliferationChannel blockers;CPZ, capsazepineCRAC, Ca2+ release-activated Ca2+ channelCTL, cytotoxic T cellsCYP3A4, cytochrome P450 3A4ER/SR, endoplasmic/sarcoplasmic reticulumHCX, H+/Ca2+ exchangersIP3, inositol 1,4,5-trisphosphateIP3R (1, 2, 3), IP3 receptor (type 1, type 2, type 3)mAb, monoclonal antibodyMCU, mitochondrial Ca2+ uniporterMCUR1, MCU uniporter regulator 1MICU (1, 2, 3), mitochondrial calcium uptake (type 1, type 2, type 3)MigrationMLCK, myosin light-chain kinaseNCX, Na+/Ca2+ exchangerNFAT, nuclear factor of activated T cellsNF-κB, nuclear factor-κBNSCLC, non-small cell lung cancerOSCC, oral squamous cell carcinoma cellsPKC, protein kinase CPMCA, plasma membrane Ca2+-ATPasePM, plasma membranePTP, permeability transition poreROS, reactive oxygen speciesRyR, ryanodine receptorSERCA, SR/ER Ca2+-ATPaseSOCE, store-operated Ca2+ entrySPCA, secretory pathway Ca2+-ATPaseStore-operated Ca2+ entryTEA, tetraethylammoniumTG, thapsigarginTPC2, two-pore channel 2TRIM, 1-(2-(trifluoromethyl) phenyl) imidazoleTRP (A, C, M, ML, N, P, V), transient receptor potential (ankyrin, canonical, melastatin, mucolipin, no mechanoreceptor potential C, polycystic, vanilloid)VGCC, voltage-gated Ca2+ channel

Identifiers

PMID28119804
PMCPMC5237760
OpenAlexW2561631604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.